Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918

Stopped early · Phase 1

Conditions studied: Cancer,, Solid Tumors, Advanced Solid Malignancies

In brief

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD6918 based on the side effects experienced by patients with advanced solid malignancies that receive daily AZD6918 alone. It is possible that AZD6918 will be administered twice daily. Then maximum tolerated doses in combination with either gemcitabine or pemetrexed will also be investigated.

Key facts

Study ID

NCT00733031

Run by

AstraZeneca

People needed

75

Starts

2008-08-01

Expected to finish

2009-03-01

Last updated by the study team

2010-12-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced solid tumors for which standard treatment does not exist or is no longer effective.
• For chemotherapy combination treatment, must be suitable for treatment with either gemcitabine or pemetrexed.
• Relatively good overall health other than cancer.

You may not qualify if…

• Poor bone marrow function (not producing enough blood cells).
• Poor liver or kidney function.
• Serious heart conditions
• History of uncontrolled epilepsy, Parkinson's disease, Alzheimer's disease, brain tumor or any uncontrolled psychiatric or nervous system condition

Where it is running

• Research Site — Aurora, Colorado, United States
• Research Site — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.